Early Signs of Alzheimer's Detected in Cerebrospinal Fluid
|
By LabMedica International staff writers Posted on 29 Dec 2016 |
|
Image: A histology of immune cells of the brain, the microglia (brown), cluster around the beta-amyloid deposits (red) in an Alzheimer’s disease model (Photo courtesy of Frank Heppner/ Charité).
An early immune response has been found in individuals with a genetic predisposition to Alzheimer's and their brains showed abnormal immune reactions as early as about seven years before the expected onset of dementia.
Emerging evidence supports a role for innate immunity and microglia in Alzheimer’s disease (AD) pathophysiology. However, no marker related to microglia has been included in the temporal evolution models of AD. Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) is a transmembrane protein involved in innate immunity and is selectively expressed by microglia and genetically linked to AD and other neurodegenerative disorders.
Scientists at the German Center for Neurodegenerative Diseases (Munich, Germany) have measured the amount of a secreted form of TREM2 (sTREM2) in cerebrospinal fluid (CSF) as a surrogate marker for microglial activation. Participants in the study were a unique cohort of 127 subjects with autosomal dominant AD and 91 healthy siblings. They were on average 40 years old and the vast majority showed no symptoms of dementia or had only minor cognitive impairments.
The team found that CSF’sTREM2 was abnormally increased five years before the expected onset of symptoms in the AD patients. They observed that CSF sTREM2 increased in mutation carriers (MCs) compared to non-carriers five years before the expected symptom onset and this difference remained significant until five years after the expected symptom onset. Changes in CSF’sTREM2 occurred after alterations were observed in markers for brain amyloidosis and neuronal injury.
Michael Ewers, Dipl. Rel. Paed., MPH, Dr. PH, a professor and a senior author of the study, said, “There are many similarities between the inherited form of Alzheimer's disease and the so-called sporadic variant, which is far more common. TREM2 levels could therefore be a biomarker used to track immune activity while Alzheimer's is progressing, irrespective of whether the disease is genetic or not. TREM2 may also serve as a therapeutic marker to monitor drug response.” The study was published on December 14, 2016, in the journal Science Translational Medicine.
Related Links:
German Center for Neurodegenerative Diseases
 (3) (1).png)
Emerging evidence supports a role for innate immunity and microglia in Alzheimer’s disease (AD) pathophysiology. However, no marker related to microglia has been included in the temporal evolution models of AD. Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) is a transmembrane protein involved in innate immunity and is selectively expressed by microglia and genetically linked to AD and other neurodegenerative disorders.
Scientists at the German Center for Neurodegenerative Diseases (Munich, Germany) have measured the amount of a secreted form of TREM2 (sTREM2) in cerebrospinal fluid (CSF) as a surrogate marker for microglial activation. Participants in the study were a unique cohort of 127 subjects with autosomal dominant AD and 91 healthy siblings. They were on average 40 years old and the vast majority showed no symptoms of dementia or had only minor cognitive impairments.
The team found that CSF’sTREM2 was abnormally increased five years before the expected onset of symptoms in the AD patients. They observed that CSF sTREM2 increased in mutation carriers (MCs) compared to non-carriers five years before the expected symptom onset and this difference remained significant until five years after the expected symptom onset. Changes in CSF’sTREM2 occurred after alterations were observed in markers for brain amyloidosis and neuronal injury.
Michael Ewers, Dipl. Rel. Paed., MPH, Dr. PH, a professor and a senior author of the study, said, “There are many similarities between the inherited form of Alzheimer's disease and the so-called sporadic variant, which is far more common. TREM2 levels could therefore be a biomarker used to track immune activity while Alzheimer's is progressing, irrespective of whether the disease is genetic or not. TREM2 may also serve as a therapeutic marker to monitor drug response.” The study was published on December 14, 2016, in the journal Science Translational Medicine.
Related Links:
German Center for Neurodegenerative Diseases
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Laboratory Software
ArtelWare
Pipette
Accumax Smart Series
Latest Pathology News
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
- First-Of-Its-Kind Test Identifies Autism Risk at Birth
- AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
- Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
- Fast Label-Free Method Identifies Aggressive Cancer Cells
- New X-Ray Method Promises Advances in Histology
- Single-Cell Profiling Technique Could Guide Early Cancer Detection
- Intraoperative Tumor Histology to Improve Cancer Surgeries
- Rapid Stool Test Could Help Pinpoint IBD Diagnosis
- AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
- Deep Learning–Based Method Improves Cancer Diagnosis
- ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
- New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more